Loading…
CERT
Certara, Inc.
NASDAQ· Healthcare· Health Information Services· CUSIP 15687V109
$10.09-0.88%Price as of Oct 23, 00:47 UTC · updated once a day, after the close
At a glance
Certara, Inc. (CERT) is listed on NASDAQ and classified in Health Information Services, part of the Healthcare sector. It is headquartered in Radnor, United States and has 1,515 employees. The company is worth $1.54B. Revenue was $418.84M in fiscal 2025, up 8.7% from the year before. It reported a net loss of $1.6M. The share price is 22.0% below its 52-week high of $12.94. 6 of the 38 superinvestors we track held it at the end of Q2 2026. The largest position belongs to Israel Englander (Millennium Management), at $16.74M. In that quarter, 4 of them opened or added to the position and 2 reduced it. No open-market insider trades in it were filed over the last 30 days.
Written from the data on this page: SEC filings (13F, Form 4, annual reports) and market prices.
Key metrics
- Market cap
- $1.54B
- P/E
- —
- Forward P/E
- 25.7x
- P/B
- 1.6x
- Dividend yield
- 0.00%
- Payout
- —
- EPS
- -$0.14
- ROE
- -2.21%
- Profit margin
- -16.22%
- Revenue growth
- +1.00%
- Beta
- 1.43
- 52-week high
- $12.94
- 52-week low
- $4.45
History
Year by year, from the annual reports; dividends from the payments themselves.
Bars are year-end balances; lines are what happened during the year.
Investors holding this
Major managers that reported this stock in their latest 13F.
- Israel EnglanderAddedMillennium Management · Q2 2026$16.74M2.56M shares · 0.0% of portfolio
- Cliff AsnessAddedAQR Capital Management · Q2 2026$13.76M2.16M shares · 0.0% of portfolio
- Two SigmaAddedTwo Sigma Investments · Q2 2026$7.24M1.1M shares · 0.0% of portfolio
Ken GriffinReducedCitadel Advisors · Q2 2026$7.16M1.09M shares · 0.0% of portfolio- Renaissance TechnologiesAddedRenaissance Technologies · Q2 2026$4.48M684.7K shares · 0.0% of portfolio
- Steve CohenReducedPoint72 Asset Management · Q2 2026$2.51M382.53K shares · 0.0% of portfolio
Price over time
▼ -65.2% over 5Y.
today you would have $226.82▼ -77.3%
Dividends reinvested, splits accounted for. Past prices say what happened, not what will.
Indicators, year by year
The last 6 closed years, each at that year’s closing price and reported numbers.
| Indicator | Median | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|---|
| Year-end price | $8.81 | $10.65 | $17.59 | $16.07 | $28.42 | $33.72 | |
| P/E | — | — | — | — | 178.6x | — | — |
| P/S | 7.8x | 3.3x | 4.5x | 7.9x | 7.6x | 15.9x | 21.2x |
| P/B | 2.5x | 1.3x | 1.6x | 2.7x | 2.4x | 4.4x | 6.3x |
| EPS | -$0.01 | -$0.08 | -$0.35 | $0.09 | -$0.09 | -$0.37 | |
| Profit margin | -3.88% | -0.38% | -3.13% | -15.62% | 4.39% | -4.64% | -20.28% |
| ROE | -1.21% | -0.15% | -1.14% | -5.29% | 1.36% | -1.27% | -6.01% |
Median of the years shown; P/E years above 200x are left out.
Fair price, seven ways
Seven formulas applied to the reported numbers, each with its assumption next to the result. None of them predicts a price.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Earnings
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
Cash flow
$9.09
Cash flow growing 5.0% a year for 10 years, discounted at 10%, then 2.5% forever.
Operating
$7.85
Sector median of 14.1x operating profit, less net debt. Banks have no EBITDA.
Dividends
—
This formula has no meaning here — usually a loss, negative cash flow, or a missing input.
How the average is calculated
The average of the method families that answered, not of the seven numbers: four of the seven start from the same earnings per share.
Cash flow $9.09+Operating $7.85÷ 2 =$8.47
$8.47
2 methods answered, across 2 families.
$6.35
Room for errors in the reported numbers.
$10.09
-16.1% from the average.
Models, not forecasts, and not investment advice. How each formula works →
Others in the same sector
Companies of similar size in Healthcare, for comparison. The columns are the same ones above, in the same order.
| Stock | Price | P/E | P/B | Dividend yield | ROE | Market cap |
|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics, Inc. | $27.53 | — | 3.4x | 0.00% | -37.35% | $1.53B |
| GENBGenerate Biomedicines, Inc. | $12.09 | — | 3.4x | 0.00% | — | $1.55B |
| INVAInnoviva, Inc. | $21.06 | 4.9x | 1.2x | 0.00% | 36.68% | $1.52B |
| AGLagilon health, inc. | $90.29 | — | 6.7x | 0.00% | -78.94% | $1.52B |
| NTLAIntellia Therapeutics, Inc. | $11.16 | — | 2.1x | 0.00% | -55.44% | $1.56B |
| GPCRStructure Therapeutics Inc. | $21.93 | — | 1.2x | 0.00% | -20.21% | $1.56B |
About the company
- 1,515
- Radnor, United States